Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants

作者：Prandoni Paolo^*

来源：European Journal of Haematology, 2012, 88(3): 185-194.

DOI：10.1111/j.1600-0609.2011.01733.x

• apixaban
• dabigatran
• deep-vein thrombosis
• post-thrombotic syndrome
• rivaroxaban
• warfarin

Deep-vein thrombosis (DVT) can have a significant impact on a patients life. In particular, the development of post-thrombotic syndrome as a long-term complication of DVT can have devastating consequences for the individual and impose a substantial economic burden on healthcare systems. Anticoagulants are the mainstay of DVT treatment; however, the current standard of care, a parenteral anticoagulant followed by a vitamin K antagonist, is associated with complex patient management, often resulting in suboptimal therapy. New, oral anticoagulants have been developed, and a direct thrombin inhibitor - dabigatran etexilate - and two direct Factor Xa inhibitors - rivaroxaban and apixaban - have completed and/or have ongoing phase III trials in the treatment of venous thromboembolism. These agents do not have the drawbacks of the vitamin K antagonists and hold promise for more effective treatment of DVT, possibly resulting in a reduction in the incidence of post-thrombotic syndrome.

• 出版日期2012-3